Ir-CPI is under clinical development by Bioxodes and currently in Phase II for Intracerebral Hemorrhage. According to GlobalData, Phase II drugs for Intracerebral Hemorrhage does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ir-CPI LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ir-CPI overview

Ir-CPI is under development of for the treatment of thrombo-inflammatory diseases and intracerebral hemorrhage (hemorrhagic stroke). It is administered as an intravenous route. Ir-CPI is a 67 amino acid protein derived from the salivary glands of the tick Ixodes ricinus. The drug candidate is a contact phase inhibitor (CPI) targeting specifically factors XIa and XIIa.

Bioxodes overview

Bioxodes is developing a portfolio of high value products derived from natural sources. The company is headquartered in Luxembourg, Belgium

For a complete picture of Ir-CPI’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.